These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 23345305)
1. Discussion of 'small-sample behavior of novel phase I cancer trial designs' by Assaf P Oron and Peter D Hoff. Carlin BP; Zhong W; Koopmeiners JS Clin Trials; 2013 Feb; 10(1):81-5; discussion 88-92. PubMed ID: 23345305 [No Abstract] [Full Text] [Related]
2. Commentary on 'Small-sample behavior of novel phase I cancer trial designs'. Cheung YK Clin Trials; 2013 Feb; 10(1):86-7; discussion 88-92. PubMed ID: 23345306 [No Abstract] [Full Text] [Related]
3. Small-sample behavior of novel phase I cancer trial designs. Oron AP; Hoff PD Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304 [TBL] [Abstract][Full Text] [Related]
4. Clinical trial design for phase 1 studies of drug combinations. Paller C Clin Adv Hematol Oncol; 2014 May; 12(5):335-7. PubMed ID: 25003492 [No Abstract] [Full Text] [Related]
5. Current issues in phase I trials: new study designs and informed consent procedures. Cavalli F; Sessa C Ann Oncol; 1999; 10 Suppl 6():147-8. PubMed ID: 10676566 [No Abstract] [Full Text] [Related]
6. Dose selection in phase I studies: why we should always go for the most effective. Haines IE J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947 [No Abstract] [Full Text] [Related]
7. Dose selection in phase I studies: why we should always go for the top. Sleijfer S; Wiemer E J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465 [No Abstract] [Full Text] [Related]
8. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs. Potter DM J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260 [TBL] [Abstract][Full Text] [Related]
9. Choice of designs and doses for early phase trials. Zhou Y Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290 [TBL] [Abstract][Full Text] [Related]
10. Should We Preclude Phase 1 Clinical Trials From Enrolling Elderly Individuals? Balducci L Cancer Control; 2015 Apr; 22(2):232-4. PubMed ID: 26068770 [No Abstract] [Full Text] [Related]
11. Three-dose-cohort designs in cancer phase I trials. Huang B; Chappell R Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082 [TBL] [Abstract][Full Text] [Related]
12. Phase 1 clinical trials nursing: determining safety and side effects on the road approval. Lindberg D ONS Connect; 2012 Jul; 27(7):10-4. PubMed ID: 22855983 [No Abstract] [Full Text] [Related]
14. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence]. Kusaba H; Tamura T Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451 [TBL] [Abstract][Full Text] [Related]
15. [A combination phase I/II study--dose escalation plan]. Yamamoto N Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175 [TBL] [Abstract][Full Text] [Related]
16. Designs for single- or multiple-agent phase I trials. Conaway MR; Dunbar S; Peddada SD Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288 [TBL] [Abstract][Full Text] [Related]
17. Dose finding with continuous outcome in phase I oncology trials. Wang Y; Ivanova A Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518 [TBL] [Abstract][Full Text] [Related]
18. Critical aspects of the Bayesian approach to phase I cancer trials. Neuenschwander B; Branson M; Gsponer T Stat Med; 2008 Jun; 27(13):2420-39. PubMed ID: 18344187 [TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trials: adapting methodology to face new challenges. Kerr DJ Ann Oncol; 1994; 5 Suppl 4():67-70. PubMed ID: 8060900 [TBL] [Abstract][Full Text] [Related]